Novo Nordisk A/S’s (NVO) “Sell” Rating Reaffirmed at HSBC

HSBC reiterated their sell rating on shares of Novo Nordisk A/S (NYSE:NVO) in a research report sent to investors on Tuesday morning.

NVO has been the subject of several other reports. Zacks Investment Research lowered Novo Nordisk A/S from a buy rating to a sell rating in a research report on Wednesday, October 10th. ValuEngine raised Novo Nordisk A/S from a sell rating to a hold rating in a research report on Saturday, October 27th. Deutsche Bank reaffirmed a buy rating on shares of Novo Nordisk A/S in a research report on Thursday, October 4th. Bank of America lowered Novo Nordisk A/S from a buy rating to a neutral rating in a research report on Monday, October 8th. Finally, Kepler Capital Markets reaffirmed a hold rating on shares of Novo Nordisk A/S in a research report on Thursday, October 18th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $64.00.

Shares of Novo Nordisk A/S stock traded up $0.27 during trading hours on Tuesday, hitting $44.94. 1,514,063 shares of the company’s stock traded hands, compared to its average volume of 1,677,285. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $58.37. The firm has a market cap of $108.83 billion, a PE ratio of 19.21, a P/E/G ratio of 2.36 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 8th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.04. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. The firm had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.33 billion. As a group, equities analysts forecast that Novo Nordisk A/S will post 2.44 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of NVO. Chicago Partners Investment Group LLC grew its stake in shares of Novo Nordisk A/S by 762.5% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 3,131 shares of the company’s stock worth $144,000 after acquiring an additional 2,768 shares during the period. Schroder Investment Management Group bought a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $182,000. Legacy Financial Advisors Inc. grew its stake in shares of Novo Nordisk A/S by 527.8% during the 3rd quarter. Legacy Financial Advisors Inc. now owns 3,886 shares of the company’s stock worth $183,000 after acquiring an additional 3,267 shares during the period. Stevens Capital Management LP bought a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $202,000. Finally, FineMark National Bank & Trust bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $212,000. Institutional investors own 6.72% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Featured Story: Stop Order

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply